International Nonproprietary Names for Pharmaceutical Substances (INN)

RECOMMENDED International Nonproprietary Names (Rec. INN): List 43

Notice is hereby given that, in accordance with paragraph 7 of the Procedure for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances [*Off. Rec. Wld Health Org.*, 1955, **60**, 3 (Resolution EB15.R7); 1969, **173**, 10 (Resolution EB43.R9)], the following names are selected as Recommended International Nonproprietary Names. The inclusion of a name in the lists of Recommended International Nonproprietary Names does not imply any recommendation of the use of the substance in medicine or pharmacy. Lists of Proposed (1–73) and Recommended (1–35) International Nonproprietary Names can be found in *Cumulative List No. 9, 1996.*

Dénominations communes internationales des Substances pharmaceutiques (DCI)

Dénominations communes internationales RECOMMANDÉES (DCI Rec): Liste 43

Il est notifié que, conformément aux dispositions du paragraphe 7 de la Procédure à suivre en vue du choix de Dénominations communes internationales recommandées pour les Substances pharmaceutiques [*Actes off. Org. mond. Santé*, 1955, **60**, 3 (résolution EB15.R7); 1969, **173**, 10 (résolution EB43.R9)] les dénominations ci-dessous sont choisises par l'Organisation mondiale de la Santé en tant que dénominations communes internationales recommandées. L'inclusion d'une dénomination dans les listes de DCI recommandées n'implique aucune recommandation en vue de l'utilisation de la substance correspondante en médecine ou en pharmacie.
On trouvera d'autres listes de Dénominations communes internationales proposées (1–73) et recommandées (1–35) dans la *Liste récapitulative No. 9, 1996.*

Denominaciones Comunes Internacionales para las Sustancias Farmacéuticas (DCI)

Denominaciones Comunes Internacionales RECOMENDADAS (DCI Rec.): Lista 43

De conformidad con lo que dispone el párrafo 7 del Procedimiento de Selección de Denominaciones Comunes Internacionales Recomendadas para las Sustancias Farmacéuticas [*Act. Of. Mund. Salud*, 1955, **60**, 3 (Resolución EB15.R7); 1969, **173**, 10 (Resolución EB43.R9)], se comunica por el presente anuncio que las denominaciones que a continuación se expresan han sido seleccionadas como Denominaciones Comunes Internacionales Recomendadas. La inclusión de una denominación en las listas de las Denominaciones Comunes Recomendadas no supone recomendación alguna en favor del empleo de la sustancia respectiva en medicina o en farmacia.
Las listas de Denominaciones Comunes Internacionales Propuestas (1–73) y Recomendadas (1–35) se encuentran reunidas en *Cumulative List No. 9, 1996.*

An ongoing review is under way of the long-standing objections to proposed International Nonproprietary Names (INN). As a result, objections have been withdrawn to the following names which are now included in this list of recommended INNs:

atizoram, atliprofen, beclamide, bicifadine, bornelone, ciadox, cloperastine, clorexolone, cloroperone, corticotropin zinc hydroxide, cresotamide, difenidol, diosmin, divabuterol, eledoisin, erityrityl tetranitrate, exepanol, fenaclon, fenoprofen, fluquazone, glutaurine, guaifylline, halazone, kebuzone, metamfepramone, meticillin, moquizone, nabilone, nonabine, norgesterone, odalprofen, oletimol, pentiapine, plauracin, sulisatin, tandamine, teopranitol, ticarcillin, tienocarbine, triclofos, triflocin, trimecaine, zolazepam

Les objections formulées de longue date contre des Dénominations communes internationales (DCI) proposées sont examinées. Des objections ont été retirées à la suite de cet examen et les noms suivants sont donc inclus dans cette liste des DCI recommandées:

atizoram, atliprofène, béclamide, bicifadine, bornélone, ciadox, clopérastine, clorexolone, cloropérone, corticotropine hydroxyde de zinc, crésotamide, difénidol, diosmine, divabutérol, élédoïsine, tétranitrate d'érityrityle, exépanol, fénaclone, fénoprofène, fluquazone, glutaurine, guaïfylline, halazone, kébuzone, métamfépramone, méticilline, moquizone, nabilone, nonabine, norgestérone, odalprofène, olétimol, pentiapine, plauracine, sulisatine, tandamine, téopranitol, ticarcilline, tiénocarbine, triclofos, triflocine, trimécaïne, zolazépam

Se ha emprendido un examen de las objeciones que se vienen formulando desde hace tiempo a las denominaciones comunes internacionales (DCI) propuestas. Como resultado, se han retirado las objeciones a las denominaciones siguientes, que ahora están incluidas en la presente lista de DCI recomendadas:

atizoram, atliprofeno, beclamida, bicifadina, bornelona, ciadox, cloperastina, clorexolona, cloroperona, corticotropina hidróxido de zinc, cresotamida, difenidol, diosmina, divabuterol, eledoisina, tetranitrato de eritritilo, exepanol, fenaclón, fenoprofeno, flucuazona, glutaurina, guaifilina, halazona, kebuzona, metanfepramona, meticilina, moquizona, nabilona, nonabina, norgesterona, odalprofeno, oletimol, pentiapina, plauracina, sulisatina, tandamina, teopranitol, ticarcilina, tienocarbina, triclofós, triflocina, trimecaína, zolazepam

Proposed INN (Latin, English, French, Spanish)	*Chemical name or description: Action and use: Molecular formula Chemical Abstracts Service (CAS) registry number: Graphic formula*
DCI Proposée	*Nom chimique ou description: Propriétés et indications: Formule brute Numéro dans le registre du CAS: Formule développée*
DCI Propuesta	*Nombre químico o descripción: Acción y uso: Fórmula empírica Número de registro del CAS: Fórmula desarrollada*

abetimusum

abetimus

d(C-A-C-A-C-A-C-A-C-A-C-A-C-A-C-A-C-A)-*P*, 5',5''',5'''',5'''''',5''''''''-tetraester with ethylenebis(oxyethylene) bis[bis[2-[6-[2-[(6-hydroxyhexyl)thio]= acetamido]hexanamido]ethyl]carbamate], complex with d(T-G-T-G-T-G-T-G-T-G-T-G-T-G-T-G-T-G-T-G) (1:4)

abétimus

complexe (4:1) entre l'acide désoxyribonucléique d(T-G-T-G-T-G-T-G-T-G-T-G-T-G-T-G-T-G) et le tétrakis[5'-hydrogénophosphate de l'acide désoxyribonucléique d(C-A-C-A-C-A-C-A-C-A-C-A-C-A-C-A-C-A)] de 6,6',6'',6'''-[éthylènebis[oxyéthylèneoxycarbonylnitrilobis[éthylèneimino= (6-oxohexane-6,1-diyl)imino(2-oxoéthane-2,1-diyl)sulfanediyl]]]tétrahexyle

abetimús

5',5''',5'''',5''''''-*P*-tetraéster del d(P-tetraéster del d(C-C-A-C-A-C-A-C-A-C-A-C-A-C-A-C-A-C-A) con bis[bis[2-[6-[2-[(6-hidroxihexil)tio]acetamido]= hexanamido]etil]carbamato] de etilenobis(oxietileno), complejo con d(T-G-T-G-T-G-T-G-T-G-T-G-T-G-T-G-T-G-T-G) (1:4)

$C_{1632}H_{2100}N_{610}O_{970}P_{156}S_4$



acidum caloxeticum

caloxetic acid

trihydrogen [*N*-[(2*S*)-2-[bis(carboxymethyl)amino]-3-(*p*-ethoxyphenyl)propyl]-*N*-[2-[bis(carboxymethyl)amino]ethyl]glycinato(5-)]calciate(3-)

acide caloxétique

trihydrogéno[*N*-[(2*S*)-2-[bis(carboxyméthyl)amino]-3-(4-éthoxyphényl)propyll]-*N*-[2-[bis(carboxyméthyl)amino]éthyl]glycinato(5-)]calciate(3-)

ácido caloxético

[*N*-[(2*S*)-2-[bis(carboximetil)amino]-3-(*p*-etoxifenil)propil]-*N*-[2-[bis(carboximetil)amino]etil]glicinato(5-)]calciato(3-) de trihidrógeno

$C_{23}H_{31}CaN_3O_{11}$



anidulafunginum

anidulafungin

(4*R*,5*R*)-4,5-dihydroxy-*N*^{2}-[[4"-(pentyloxy)-*p*-terphenyl-4-yl]carbonyl]-L-ornithyl-L-threonyl-*trans*-4-hydroxy-L-prolyl-(*S*)-4-hydroxy-4-(*p*-hydroxyphenyl)-L-threonyl-L-threonyl-(3*S*,4*S*)-3-hydroxy-4-methyl-L-proline cyclic (6→1)-peptide

anidulafungine

N-[(2*R*,6*S*,9*S*,11*R*,12*R*,14a*S*,15*S*,16*S*,20*S*,23*S*,25a*S*)-23-[(1*S*,2*S*)-1,2-dihydroxy-2-(4-hydroxyphényl)éthyl]-2,11,12,15-tétrahydroxy-6,20-bis[(1*R*)-1-hydroxyéthyl]-16-méthyl-5,8,14,19,22,25-hexaoxotétracosahydro-1*H*-dipyrrolo[2,1-*c*:2',1'-*l*][1,4,7,10,13,16]hexaazacyclohénicosén-9-yl]-4"-(pentyloxy)-1,1':4',1"-terphényle-4-carboxamide

anidulafungina

péptido (6→1)-cíclico (4*R*,5*R*)-4,5-dihidroxi-*N*^{2}-[4"-(pentiloxi)-*p*-terfenil-4-il]carbonil]-L-ornitil-L-treonil-*trans*-4-hidroxi-L-prolil-(*S*)-4-hidroxi-4-(*p*-hidroxifenil)-L-treonil-L-treonil-(3*S*,4*S*)-3-hidroxi-4-metil-L-prolina

$C_{58}H_{73}N_7O_{17}$



artenimolum

artenimol (3*R*,5a*S*,6*R*,8a*S*,9*R*,10*S*,12*R*,12a*R*)-decahydro-3,6,9-trimethyl-3,12-epoxy-12*H*-pyrano[4,3-*j*]-1,2-benzodioxepin-10-ol

arténimol (3*R*,5aS,6*R*,8a*S*,9*R*,10*S*,12*R*,12a*R*)-3,6,9-triméthyldécahydro-3,12-époxypyrano[4,3-*j*]-1,2-benzodioxépin-10-ol

artenimol (3*R*,5a*S*,6*R*,8a*S*,9*R*,10*S*,12*R*,12a*R*)-decahidro-3,6,9-trimetil-3,12-epoxi-12*H*-pirano[4,3-*j*]-1,2-benzodioxepin-10-ol

$C_{15}H_{24}O_5$



atizoramum

atizoram — tetrahydro-5-[4-methoxy-3-[(1*S*,2*S*,4*R*)-2-norbornyloxy]phenyl]-2(1*H*)-pyrimidinone

atizoram — 5-[3-[[(1*S*,2*S*,4*R*)-bicyclo[2.2.1]hept-2-yl]oxy]-4-méthoxyphényl]=tétrahydropyrimidin-2(1*H*)-one

atizoram — tetrahidro-5-[4-metoxi-3-[(1*S*,2*S*,4*R*)-2-norborniloxi]fenil]-2(1*H*)-pirimidinona

$C_{18}H_{24}N_2O_3$



atliprofenum

atliprofen — (±)-*p*-3-thienylhydratropic acid

atliprofène — acide (*RS*)-2-[4-(thiophén-3-yl)phényl]propanoïque

atliprofeno — ácido (±)-*p*-3-tienilhidratrópico

$C_{13}H_{12}O_2S$



and enantiomer
et énantiomère
y enantiómero

beclamidum

beclamide — *N*-benzyl-β-chloropropionamide

béclamide — *N*-benzyl-3-chloropropanamide

beclamida — *N*-bencil-β-cloropropionamida

$C_{10}H_{12}ClNO$



bexlosteridum

bexlosteride (4a*R*,10b*R*)-8-chloro-1,4,4a,5,6,10b-hexahydro-4-methylbenzo[*f*]quinolin-3(2*H*)-one

bexlostéride (4a*R*,10b*R*)-8-chloro-4-méthyl-1,4,4a,5,6,10b-hexahydrobenzo[*f*]quinoléin-3(2*H*)-one

bexlosterida (4a*R*,10b*R*)-8-cloro-1,4,4a,5,6,10b-hexahidro-4-metilbenzo[*f*]quinolin-3(2*H*)-ona

$C_{14}H_{16}ClNO$



bicifadinum

bicifadine (±)-1-*p*-tolyl-3-azabicyclo[3.1.0]hexane

bicifadine (1*RS*,5*SR*)-1-(4-méthylphényl)-3-azabicyclo[3.1.0]hexane

bicifadina (±)-1-*p*-tolil-3-azabiciclo[3.1.0]hexano

$C_{12}H_{15}N$



and enantiomer
et énantiomère
y enantiómero

bornelonum

bornelone 5-(3,3-dimethyl-2-norbornylidene-3-penten-2-one

bornélone (3*E*)-5-[(1*RS*,2*E*,4*SR*)-3,3-diméthylbicyclo[2.2.1]hept-2-ylidène]pent-3-én-2-one

bornelona 5-(3,3-dimetil-2-norbornilideno-3-penten-2-ona

$C_{14}H_{20}O$



and enantiomer
et énantiomère
y enantiómero

cadrofloxacinum

cadrofloxacin (-)-1-cyclopropyl-8-(difluoromethoxy)-6-fluoro-1,4-dihydro-7-[(*S*)-3-methyl-1-piperazinyl]-4-oxo-3-quinolinecarboxylic acid

cadrofloxacine (-)-acide 1-cyclopropyl-8-(difluorométhoxy)-6-fuoro-7-[(3*S*)-3-méthylpipérazin-1-yl]-4-oxo-1,4-dihydroquinoléine-3-carboxylique

cadrofloxacino ácido (-)-1-ciclopropil-8-(difluorometoxi)-6-fluoro-1,4-dihidro-7-[(*S*)-3-metil-1-piperazinil]-4-oxo-3-quinolinacarboxílico

$C_{19}H_{20}F_3N_3O_4$



cefmatilenum

cefmatilen (-)-(6*R*,7*R*)-7-[2-(2-amino-4-thiazolyl)glyoxylamido]-8-oxo-3-[[(*v*-triazol-4-ylthio)methyl]thio]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7^2-(*Z*)-oxime

cefmatilène (-)-acide (6*R*,7*R*)-7-[[(*Z*)-2-(2-aminothiazol-4-yl)-2-(hydroxyimino)acétyl]=amino]-8-oxo-3-[[[(1*H*-1,2,3-triazol-4-yl)sulfanyl]méthyl]sulfanyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ène-2-carboxylique

cefmatileno 7^2-(*Z*)-oxima del ácido (-)-(6*R*,7*R*)-7-[2-(2-amino-4-tiazolil)glioxilamido]-8-oxo-3-[[(*v*-triazol-4-iltio)metil]tio]-5-tia-1-azabiciclo[4.2.0]oct-2-eno-2-carboxílico

$C_{15}H_{14}N_8O_5S_4$



ciadoxum

ciadox cyanoacetic acid (2-quinoxalinylmethylene)hydrazide N^1,N^4-dioxide

ciadox 2-cyano-2'-[(*E*)-(quinoxalin-2-yl 1,4-dioxyde)méthylène]acétohydrazide

ciadox N^1,N^4-dióxido de la (2-quinoxalinilmetileno)hidrazida del ácido cianoacético

$C_{12}H_9N_5O_3$



cilengitidum

cilengitide — cyclo(L-arginylglycyl-L-α-aspartyl-D-phenylalanyl-*N*-methyl-L-valyl)

cilengitide — cyclo[L-arginyl-glycyl-L-α-aspartyl-D-phénylalanyl-(*N*-méthyl-L-valyl)]

cilengitida — ciclo(L-arginilglicil-L-a-aspartil-D-fenilalanil-*N*-metil-L-valil)

$C_{27}H_{40}N_8O_7$



cipemastatum

cipemastat — (α*R*,β*R*)-β-(cyclopentylmethyl)-γ-oxo-α-[(3,4,4-trimethyl-2,5-dioxo-1-imidazolidinyl)methyl]-1-piperidinebutyrohydroxamic acid

cipémastat — (2*R*,3*R*)-3-(cyclopentylméthyl)-*N*-hydroxy-4-oxo-4-(pipéridin-1-yl)-2-[(3,4,4-triméthyl-2,5-dioxoimidazolidin-1-yl)méthyl]butanamide

cipemastat — ácido (α*R*,β*R*)-β-(ciclopentilmetil)-γ-oxo-α-[(3,4,4-trimetil-2,5-dioxo-1-imidazolidinil)metil]-1-piperidinabutirohidroxámico

$C_{22}H_{36}N_4O_5$



cloperastinum

cloperastine — 1-{2-[(*p*-chloro-α-phenylbenzyl)oxy]}piperidine

clopérastine — 1-[2-[(*RS*)-(4-chlorophényl)phénylméthoxy]éthyl]pipéridine

cloperastina — 1-{2-[(4-cloro-α-fenilbencil)oxi]etil}piperidina

$C_{20}H_{24}ClNO$



and enantiomer
et énantiomère
y enantiómero

clorexolonum

clorexolone — 6-chloro-2-cyclohexyl-3-oxo-5-isoindolinesulfonamide

clorexolone — 6-chloro-2-cyclohexyl-3-oxo-2,3-dihydro-1*H*-isoindole-5-sulfonamide

clorexolona — 6-cloro-2-ciclohexil-3-oxo-5-isoindolinosulfonamida

$C_{14}H_{17}ClN_2O_3S$



cloroperonum

cloroperone — 4- [4-(*p*-chlorobenzoyl)piperidino]-4´-fluorobutyrophenone

cloropérone — 4-[4-(4-chlorobenzoyl)pipéridin-1-yl]-1-(4-fluorophényl)butan-1-one

cloroperona — 4- [4-(*p*-clorobenzoil)piperidino]-4´-fluorobutirofenona

$C_{22}H_{23}ClFNO_2$



corticotropinum zinci hydroxydum

corticotropin zinc hydroxide — a preparation of purified corticotropin adsorbed on zinc hydroxide

corticotropine hydroxyde de zinc — préparation de corticotropine purifiée adsorbée sur l'hydroxyde de zinc

corticotropina hidróxido de zinc — preparación de corticotropina purificada adsorbida en hidróxido de zinc

cresotamidum

cresotamide — 2,3-cresotamide

crésotamide — 2-hydroxy-3-méthylbenzamide

cresotamida — 2,3-cresotamida

$C_8H_9NO_2$



difenidolum

difenidol — α,α-diphenyl-1-piperidinebutanol

difénidol — 1,1-diphényl-4-(pipérindin-1-yl)butan-1-ol

difenidol — 1,1-difenil-4-piperidinobutanol

$C_{21}H_{27}NO$



diosminum

diosmin — 3′,5,7-trihydroxy-4′-methoxyflavone 7-[6-*O*-(6-deoxy-α-L-mannopyranosyl)-β-D-glucopyranoside

diosmine — 7-[[6-*O*-(6-désoxy-α-L-mannopyranosyl)-β-D-glucopyranosyl]oxy]-5-hydroxy-2-(3-hydroxy-4-méthoxyphényl)-4*H*-1-benzopyran-4-one

diosmína — 7-[6-*O*-desoxi-α-L-manopiranosil)-β-D-glucopiranósido de 3′,5,7-trihydroxi-4′-metoxiflavona

$C_{28}H_{32}O_{15}$



divabuterolum

divabuterol — (±)-5-[2-(*tert*-butylamino)-1-hydroxyethyl]-*m*-phenylene dipivalate

divabutérol — bis(2,2-diméthylpropanoate) de 5-[(1*RS*)-2-[(1,1-diméthyléthyl)amino]-1-hydroxyéthyl]-1,3-phénylène

divabuterol — dipivalato de (±)-5-[2-(*terc*-butilamino)-1-hidroxietil]-*m*-fenileno

$C_{22}H_{35}NO_5$



and enantiomer
et énantiomère
y enantiómero

eledoisinum

eledoisin — 5-oxo-L-prolyl-L- prolyl-L-seryl-L-lysyl-L-aspartyl-L-alanyl-L-phenylalanyl-L-isoleucylglycyl-L-leucyl-L-methioninamide

elédoïsine — (5-oxo-L-prolyl)-L-prolyl-L-seryl-L-lysyl-L-aspartyl-L-alanyl-L-phénylalanyl-L-isoleucyl-glycyl-L-leucyl-L-méthioninamide

eledoisina — 5-oxo-L-prolil-L- prolil-L-seril-L-lisil-L-aspartil-L-alanil-L-fenilalanil-L-isoleucilglicil-L-leucil-L-metioninamida

$C_{54}H_{85}N_{13}O_{15}S$



eritrityli tetranitras

eritrityl tetranitrate — erythritol tetranitrate

tétranitrate d'éritrityle — tétranitrate de (2*R*,3*S*)-butane-1,2,3,4-tétryle

tetranitrato de eritritilo — tetranitrato de eritritol

$C_4H_6N_4O_{12}$



esketaminum
esketamine

(*S*)-2-(*o*-chlorophenyl)-2-(methylamino)cyclohexanone

eskétamine

(2*S*)-2-(2-chlorophényl)-2-(méthylamino)cyclohexanone

esketamina

(*S*)-2-(*o*-clorofenil)-2-(metilamino)ciclohexanona

$C_{13}H_{16}ClNO$



etanerceptum
etanercept

1-235-tumor necrosis factor receptor (human) fusion protein with 236-467-immunoglobulin G1 (human γ1-chain Fc fragment), dimer

étanercept

1-235-récepteur du facteur de nécrose tumorale (humain)-236-467-immunoglobuline G1 (chaîne γ1 du fragment Fc humain), dimère

etanercept

dímero de la proteína de fusión del 1-235 receptor del factor de necrosis tumoral (humano) con la 236-467-immunoglobulina G1 (cadena γ1 del fragmento Fc humano)

$C_{2224}H_{3472}N_{618}O_{701}S_{36}$ (monomer)

LPAQVAFTPY	APEPGSTCRL	REYYDQTAQM	CCSKCSPGQH
AKVFCTKTSD	TVCDSCEDST	YTQLWNWVPE	CLSCGSRCSS
DQVETQACTR	EQNRICTCRP	GWYCALSKQE	GCRLCAPLRK
CRPGFGVARP	GTETSDVVCK	PCAPGTFSNT	TSSTDICRPH
QICNVVAIPG	NASMDAVCTS	TSPTRSMAPG	AVHLPQPVST
RSQHTQPTPE	PSTAPSTSFL	LPMGPSPPAE	GSTGDEPKSC
DKTHTCPPCP	APELLGGPSV	FLFPPKPKDT	LMISRTPEVT
CVVVDVSHED	PEVKFNWYVD	GVEVHNAKTK	PREEQYNSTY
RVVSVLTVLH	QDWLNGKEYK	CKVSNKALPA	PIEKTISKAK
GQPREPQVYT	LPPSREEMTK	NQVSLTCLVK	GFYPSDIAVE
WESNGQPENN	YKTTPPVLDS	DGSFFLYSKL	TVDKSRWQQG
NVFSCSVMHE	ALHNHYTQKS	LSLSPGK	

2

exatecanum

exatecan

(1*S*,9*S*)-1-amino-9-ethyl-5-fluoro-1,2,3,9,12,15-hexahydro-9-hydroxy-4-methyl-10*H*,13*H*-benzo[*de*]pyrano[3',4':6,7]indolizino[1,2-*b*]quinoline-10,13-dione

exatécan

(1*S*,9*S*)-1-amino-9-éthyl-5-fluoro-9-hydroxy-4-méthyl-1,2,3,9,12,15-hexahydro-10*H*,13*H*-benzo[*de*]pyrano[3',4':6,7]indolizino[1,2-*b*]quinoléine-10,13-dione

exatecán

(1*S*,9*S*)-1-amino-9-etil-5-fluoro-1,2,3,9,12,15-hexahidro-9-hidroxi-4-metil-10*H*,13*H*-benzo[*de*]pirano[3',4':6,7]indolizino[1,2-*b*]quinolina-10,13-diona

$C_{24}H_{22}FN_3O_4$



exepanolum

exepanol

(±)-*cis*-2,3,4,5-tetrahydro-3-(methylamino)-1-benzoxepin-5-ol

exépanol

(3*RS*,5*SR*)-3-(méthylamino)-2,3,4,5-tétrahydro-1-benzoxépin-5-ol

exepanol

(±)-*cis*-2,3,4,5-tetrahidro-3-(metilamino)-1-benzoxepin-5-ol

$C_{11}H_{15}NO_2$



and enantiomer
et énantiomère
y enantiómero

falnidamolum

falnidamol

8-(3-chloro-4-fluoroanilino)-2-[(1-methyl-4-piperidyl)amino]pyrimido[5,4-*d*]pyrimidine

falnidamol

N^8-(3-chloro-4-fluorophényl)-N^2-(1-méthylpipéridin-4-yl)pyrimido[5,4-*d*]pyrimidine-2,8-diamine

falnidamol

8-(3-cloro-4-fluoroanilino)-2-[(1-metil-4-piperidil)amino]pirimido[5,4-*d*]pirimidina

$C_{18}H_{19}ClFN_7$



fenaclonum

fenaclon — 3-chloro-*N*-phenethylpropionamide

fénaclone — 3-chloro-*N*-(2-phényléthyl)propanamide

fenaclona — 3-cloro-*N*-fenetilpropionamida

$C_{11}H_{14}ClNO$



fenoprofenum

fenoprofen — (±)-*m*-phenoxyhydratropic acid

fénoprofène — acide (*RS*)-2-(3-phénoxyphényl)propanoïque

fenoprofeno — ácido (±)-*m*-fenoxihidratrópico

$C_{15}H_{14}O_3$



and enantiomer
et énantiomère
y enantiómero

finrozolum

finrozole — *p*-[3-(*p*-fluorophenyl)-2-hydroxy-1-(1*H*-1,2,4-triazol-1-yl)propyl]benzonitrile

finrozole — 4-[3-(4-fluorophényl)-2-hydroxy-1-(1*H*-1,2,4-triazol-1-yl)propyl]benzonitrile

finrozol — *p*-[3-(*p*-fluorofenil)-2-hidroxi-1-(1*H*-1,2,4-triazol-1-il)propil]benzonitrilo

$C_{18}H_{15}FN_4O$



fluquazonum

fluquazone

fluquazone

flucuazona

6-chloro-4-phenyl-1-(2,2,2-trifluoroethyl)-2(1*H*)-quinazolinone

6-chloro-4-phényl-1-(2,2,2-trifluoroéthyl)quinazolin-2(1*H*)-one

6-cloro-4-fenil-1-(2,2,2-trifluoroetil)-2(1*H*)-quinazolinona

$C_{16}H_{10}ClF_3N_2O$



fosfructosum

fosfructose

fosfructose

fosfructosa

D-fructose 1,6-bis(dihydrogen phosphate)

1,6-bis(dihydrogénophosphate) de D-*arabino*-2-hexulofuranose

1,6-bis(dihidrógenofosfato) de D-fructosa

$C_6H_{14}O_{12}P_2$



and epimer at C*
et l'épimère en C*
y el epímero en el C*

frakefamidum

frakefamide

frakéfamide

frakefamida

L-tyrosyl-D-alanyl-*p*-fluoro-L-phenylalanyl-L-phenylalaninamide

L-tyrosyl-D-alanyl-(4-fluoro-L-phénylalanyl)-L-phénylalaninamide

L-tirosil-D-alanil-*p*-fluoro-L-fenilalanil-L-fenilalaninamida

$C_{30}H_{34}FN_5O_5$



ganstigminum

ganstigmine — (4a*S*,9a*S*)-2,3,4,4a,9,9a-hexahydro-2,4a,9-trimethyl-1,2-oxazino[6,5-*b*]indol-6-yl *o*-ethylcarbanilate

ganstigmine — (2-éthylphényl)carbamate de (4a*S*,9a*S*)-2,4a,9-triméthyl-2,3,4,4a,9,9a-hexahydro-1,2-oxazino[6,5-*b*]indol-6-yle

ganstigmina — *o*-etilcarbanilato de (4a*S*,9a*S*)-2,3,4,4a,9,9a-hexahidro-2,4a,9-trimetil-1,2-oxazino[6,5-*b*]indol-6-ilo

$C_{22}H_{27}N_3O_3$



gemifloxacinum

gemifloxacin — (±)-7-[3-(aminomethyl)-4-oxo-1-pyrrolidinyl]-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid, 7^4-(*Z*)-(*O*-methyloxime)

gémifloxacine — acide 7-[(3*RS*,4*Z*)-3-(aminométhyl)-4-(méthoxyimino)pyrrolidin-1-yl]-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphtyridine-3-carboxylique

gemifloxacino — 7^4-(Z)-(*O*-metiloxima) del ácido (±)-7-[3-(aminometil)-4-oxo-1-pirrolidinil]-1-ciclopropil-6-fluoro-1,4-dihidro-4-oxo-1,8-naftiridina-3-carboxílico

$C_{18}H_{20}FN_5O_4$



and enantiomer
et énantiomère
y enantiómero

glutaurinum

glutaurine — *N*-(2-sulfoethyl)-L-glutamine

glutaurine — acide (2*S*)-2-amino-5-oxo-5-[(2-sulfoéthyl)amino]pentanoïque

glutaurina — *N*-(2-sulfoetil)-L-glutamina

$C_7H_{14}N_2O_6S$



guaifyllinum

guaifylline — 3-(*o*-methoxyphenoxy)-1,2 propanediol compound with theophylline

guaïfylline — composé équimoléculaire de 1,3-diméthyl-3,7-dihydro-1*H*-purine-2,6-dione et de (2*RS*)-3-(2-méthoxyphénoxy)propane-1,2-diol

guaifilina — 3-(o-metoxifenoxi)-1,2 propanodiol compuesto con teofilina

$C_7H_8N_4O_2.C_{10}H_{14}O_4$



halazonum

halazone — *p*-(dichlorosulfamoyl)benzoic acid

halazone — acide 4-(dichlorosulfamoyl)benzoïque

halazona — ácido-*p*-(diclorosulfamoil)benzoico

$C_7H_5Cl_2NO_4S$



ibritumomabum tiuxetanum

ibritumomab tiuxetan

immunoglobulin G1, anti-(human CD20 (antigen)) (mouse monoclonal IDEC-Y2B8 γ1-chain), disulfide with mouse monoclonal IDEC-Y2B8 κ-chain, dimer, *N*-[2-[bis(carboxymethyl)amino]-3-(4-isothiocyanatophenyl)propyl]-*N*-[2-[bis(carboxymethyl)amino]propyl]glycine conjugate

ibritumomab tiuxétan

produit de la réaction entre l'immunoglobuline G1, anti-(antigène CD20 humain) (chaîne γ1 de l'anticorps monoclonal de souris IDEC-Y2B8), dimère du disulfure avec la chaîne κ de l'anticorps monoclonal de souris IDEC-Y2B8 et la *N*-[2-[bis(carboxyméthyl)amino]-3-(4-isothiocyanatophényl)propyl]-*N*-[2-[bis(carboxyméthyl)amino]propyl]glycine

ibritumomab tiuxetán

N-[[4-[(2*S*)-2-[bis(carboximetil)amino]-3-[[(2*RS*)-2-[bis(carboximetil)=amino]propil](carboximetil)amino]propil]fenil]tiocarbamoil]=inmunoglobulina G1, anti-(antígeno CD20 humano) (cadena γ1 del anticuerpo monoclonal quimérico hombre-ratón IDEC-Y2B8), dímero del disulfuro con la cadena κ del anticuerpo monoclonal quimérico hombre-ratón IDEC-Y2B8



idremcinalum

idremcinal

8,9-didehydro-*N*-demethyl-9-deoxo-6-deoxy-6,9-epoxy-*N*-isopropylerythromycin

idremcinal

(2*R*,3*R*,4*S*,5*R*,8*R*,9*S*,10*S*,11*R*,12*R*)-5-éthyl-3,4-dihydroxy-2,4,8,10,12,14-hexaméthyl-9-[(3-*C*-méthyl-3-*O*-méthyl-2,6-didésoxy-α-L-*ribo*-hexopyranosyl)oxy]-11-[3-[méthyl(1-méthyléthyl)amino]-3,4,6-tridésoxy-β-D-*xylo*-hexopyranosyl]oxy]-6,15-dioxabicyclo[10.2.1]pentadec-1(14)-én-7-one

idremcinal

8,9-dideshidro-*N*-desmetil-9-desoxo-6-desoxi-6,9-epoxi-*N*-isopropileritromicina

$C_{39}H_{69}NO_{12}$



ilodecakinum

ilodecakin — interleukin 10 (human clone pH15C)

ilodécakine — interleukine 10 (clone humain pH15C)

ilodecakina — interleuquina 10 (clon humano pH15C)

```
SPGQGTQSEN  SCTHFPGNLP  NMLRDLRDAF  SRVKTFFQMK
DQLDNLLLKE  SLLEDFKGYL  GCQALSEMIQ  FYLEEVMPQA
ENQDPDIKAH  VNSLGENLKT  LRLRLRRCHR  FLPCENKSKA
VEQVKNAFNK  LQEKGIYKAM  SEFDIFINYI  EAYMTMKIRN
```

izonsteridum

izonsteride — (4a*R*,10b*R*)-8-[(4-ethyl-2-benzothiazolyl)thio]-1,4,4a,5,6,10b-hexahydro-4,10b-dimethylbenzo[*f*]quinolin-3(2*H*)-one

izonstéride — (4a*R*,10b*R*)-8-[(4-éthylbenzothiazol-2-yl)sulfanyl]-4,10b-diméthyl-1,4,4a,5,6,10b-hexahydrobenzo[*f*]quinoléin-3(2*H*)-one

izonsterida — (4a*R*,10b*R*)-8-[(4-etil-2-benzotiazolil)tio]-1,4,4a,5,6,10b-hexahidro-4,10b-dimetilbenzo[*f*]quinolin-3(2*H*)-ona

$C_{24}H_{26}N_2OS_2$



kebuzonum

kebuzone — 4-(3-oxobutyl)-1,2-diphenyl-3,5-pyrazolidinedione

kébuzone — 4-(3-oxobutyl)-1,2-diphénylpyrazolidine-3,5-dione

kebuzona — 4-(3-oxobutil)-1,2-difenil-3,5-pirazolidinadiona

$C_{19}H_{18}N_2O_3$



lasofoxifenum

lasofoxifene (-)-*cis*-5,6,7,8-tetrahydro-6-phenyl-5-[*p*-[2-(1-pyrrolidinyl)ethoxy]phenyl]-2-naphthol

lasofoxifène (-)-(5*RS*,6*SR*)-6-phényl-5-[4-[2-(pyrrolidin-1-yl)éthoxy]phényl]-5,6,7,8-tétrahydronaphtalén-2-ol

lasofoxifeno (-)-*cis*-5,6,7,8-tetrahidro-6-fenil-5-[*p*-[2-(1-pirrolidinil)etoxi]fenil]-2-naftol

$C_{28}H_{31}NO_2$



or enantiomer
ou énantiomère
o enantiómero

liaterminum

liatermin *N*-methionylneurotrophic factor (human glial-derived), dimer

liatermine *N*-méthionylfacteur neurotrophique (humain, dérivé de la glia), dimère

liatermina dímero del factor *N*-metionilneurotrófico (humano derivado de la glia)

$C_{1290}H_{2110}N_{420}O_{394}S_{18}$



licarbazepinum

licarbazepine 10,11-dihydro-10-hydroxy-5*H*-dibenz[*b*,*f*]azepine-5-carboxamide

licarbazépine (10*RS*)-10-hydroxy-10,11-dihydro-5*H*-dibenzo[*b*,*f*]azépine-5-carboxamide

licarbazepina 10,11-dihidro-10-hidroxi-5*H*-dibenz[*b*,*f*]azepina-5-carboxamida

$C_{15}H_{14}N_2O_2$



and enantiomer
et énantiomère
y enantiómero

mepolizumabum

mepolizumab — immunoglobulin G1, anti-(human interleukin 5) (human-mouse monoclonal SB-240563 γ1-chain), disulfide with human-mouse monoclonal SB-240563 κ-chain, dimer

mépolizumab — immunoglobuline G1, anti-(interleukine 5 humaine) (chaîne γ1 de l'anticorps monoclonal de souris SB-240563 humanisé), dimère du disulfure avec la chaîne κ de l'anticorps monoclonal de souris SB-240563 humanisé

mepolizumab — inmunoglobulina G1, anti-(interleukina 5 humana) (cadena γ1 del anticuerpo monoclonal de ratón SB-240563 humanizado), dímero del disulfuro con la cadena κ del anticuerpo monoclonal de ratón SB-240563 humanizado

metamfepramonum

metamfepramone — 2-(dimethylamino)propiophenone

métamfépramone — (2*RS*)-2-(diméthylamino)-1-phénylpropan-1-one

metanfepramona — 2-(dimetilamino)propiofenona

$C_{11}H_{15}NO$



and enantiomer
et énantiomère
y enantiómero

meticillinum

meticillin — 6-(2,6 dimethoxybenzamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid

méticilline — acide (2*S*,5*R*,6*R*)-6-[(2,6-diméthoxybenzoyl)amino]-3,3-diméthyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylique

meticilina — ácido 6-(2,6-dimetoxibenzamido)-3,3-dimetil-7-oxo-4-tia-1-azabiciclo-[3.2.0]heptano-2-carboxílico

$C_{17}H_{20}N_2O_6S$



moquizonum

moquizone — 2,3-dihydro-1-(morpholinoacetyl)-3-phenyl-4(1*H*)-quinazolinone

moquizone — 1-(morpholin-4-ylacétyl)-3-phényl-2,3-dihydroquinazolin-4(1*H*)-one

moquizona — 1-(2-morfolinoacetil)-3-fenil-2,3-dihidro-4-(1*H*)-quinazolinona

$C_{20}H_{21}N_3O_3$



nabilonum

nabilone (±)-*trans*-3-(1,1-dimethylheptyl)-6,6a,7,8,10,10a-hexahydro-1-hydroxy-6,6-dimethyl-9*H*-dibenzo[*b*,*d*]pyran-9-one

nabilone (6a*RS*,10a*RS*)-3-(1,1-diméthylheptyl)-1-hydroxy-6,6-diméthyl-6,6a,7,8,10,10a-hexahydro-9*H*-dibenzo[*b*,*d*]pyran-9-one

nabilona (±)-*trans*-3-(1,1-dimetilheptil)-6,6a,7,8,10,10a-hexahidro-1-hidroxi-6,6-dimetil-9*H*-dibenzo[*b*,*d*]piran-9-ona

$C_{24}H_{36}O_3$



and enantiomer
et énantiomère
y enantiómero

nonabinum

nonabine 7-(1,2-dimethylheptyl)-2,2-dimethyl-4-(4-pyridyl)-2*H*-1-benzopyran-5-ol

nonabine 7-(1,2-diméthylheptyl)-2,2-diméthyl-4-(pyridin-4-yl)-2*H*-1-benzopyran-5-ol

nonabina 7-(1,2-dimetilheptil)-2,2-dimetil-4-(4-piridil)-2*H*-1-benzopiran-5-ol

$C_{25}H_{33}NO_2$



norgesteronum

norgesterone — 17-hydroxy-19-nor-17α-pregna-5(10),20-dien-3-one

norgestérone — 17-hydroxy-19-nor-17α-prégna-5(10),20-dién-3-one

norgesterona — 17-hidroxi-19-nor-17α-pregna-5(10),20-dieno-3-ona

$C_{20}H_{28}O_2$



odalprofenum

odalprofen — methyl (±)-*m*-(α-imidazol-1-ylbenzyl)hydratropate

odalprofène — mélange d'isomères du 2-[3-[(1*H*-imidazol-1-yl)phénylméthyl]phényl]propanoate de méthyle

odalprofeno — (±)-*m*-(α-imidazol-1-ilbencil)hidratropato de metilo

$C_{20}H_{20}N_2O_2$



olanexidinum

olanexidine — 1-(3,4-dichlorobenzyl)-5-octylbiguanide

olanexidine — 1-(3,4-dichlorobenzyl)-5-octylbiguanide

olanexidina — 1-(3,4-diclorobencil)-5-octilbiguanida

$C_{17}H_{27}Cl_2N_5$



oletimolum

oletimol — *o*-(*N*-benzylacetimidoyl)phenol

olétimol — 2-[(*E*)-1-(benzylimino)éthyl]phénol

oletimol — *o*-(*N*-bencilacetimidoil)fenol

$C_{15}H_{15}NO$



pentiapinum

pentiapine — 5-(4-methyl-1-piperazinyl)imidazo[2,1-*b*][1,3,5]benzothiadiazepine

pentiapine — 5-(4-méthylpipérazin-1-yl)imidazo[2,1-*b*][1,3,5]benzothiadiazépine

pentiapina — 5-(4-metil-1-piperazinil)imidazo[2,1-*b*][1,3,5]benzotiadiazepina

$C_{15}H_{17}N_5S$



pibrozelesinum

pibrozelesin — methyl (*S*)-8-(bromomethyl)-3,6,7,8-tetrahydro-4-hydroxy-2-methyl-6-[(5,6,7-trimethoxyindol-2-yl)carbonyl]benzo[1,2-*b*:4,3-*b*']dipyrrole-1-carboxylate, 4-methyl-1-piperazinecarboxylate (ester)

pibrozélésine — (8*S*)-8-(bromométhyl)-2-méthyl-4-[[(4-méthylpipérazin-1-yl)carbonyl]oxy]-6-[(5,6,7-triméthoxy-1*H*-indol-2-yl)carbonyl]-3,6,7,8-tétrahydrobenzo=[1,2-*b*:4,3-*b*']dipyrrole-1-carboxylate de méthyle

pibrozelesina — (8*S*)-(bromometil)-3,6,7,8-tetrahidro-2-metil-4-[[(4-metil-1-piperazinil)=carbonil]oxi]-6-[(5,6,7-trimetoxi-1*H*-indol-2-il)carbonil]benzo=[1,2-*b*:4,3-*b*']dipirrol-1-carboxilato de metilo

$C_{32}H_{36}BrN_5O_8$



pimecrolimusum

pimecrolimus

(3*S*,4*R*,5*S*,8*R*,9*E*,12*S*,14*S*,15*R*,16*S*,18*R*,19*R*,26a*S*)-3-[(*E*)-2-[(1*R*,3*R*,4*S*)-4-chloro-3-methoxycyclohexyl]-1-methylvinyl]-8-ethyl-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-5,19-dihydroxy-14,16-dimethoxy-4,10,12,18-tetramethyl-15,19-epoxy-3*H*-pyrido[2,1-*c*] [1,4]oxaazacyclotricosine-1,7,20,21(4*H*,23*H*)-tetrone

pimécrolimus

(18*E*)-(1*R*,9*S*,12*S*,13*R*,14*S*,17*R*,21*S*,23*S*,24*R*,25*S*,27*R*)-12-[(*E*)-2-[(1*R*,3*R*,4*S*)-4-chloro-3-méthoxycyclohexyl]-1-méthyléthényl]-17-éthyl-1,14-dihydroxy-23,25-diméthoxy-13,19,21,27-tétraméthyl-11,28-dioxa-4-azatricyclo[22.3.1.$0^{4,9}$]octacos-18-ène-2,3,10,16-tétrone

pimecrolimús

(3*S*,4*R*,5*S*,8*R*,9*E*,12*S*,14*S*,15*R*,16*S*,18*R*,19*R*,26a*S*)-3-[(*E*)-2-[(1*R*,3*R*,4*S*)-4-cloro-3-metoxiciclohexil]-1-metilvinil]-8-etil-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahidro-5,19-dihidroxi-14,16-dimetoxi-4,10,12,18-tetrametil-15,19-epoxi-3*H*-pirido[2,1-*c*] [1,4]oxaazaciclotricosina-1,7,20,21(4*H*,23*H*)-tetrona

$C_{43}H_{68}ClNO_{11}$



plauracinum

plauracin

an antibiotic complex obtained from cultures of *Actinoplanes auranticolor* ATCC 31011

plauracine

antibiotique extrait de cultures d'*Actinoplanes auranticolor* (ATCC 31011) composé principalement d'une lactone macrocyclique et d'un depsipeptide

plauracina

antibiótico complejo, mezcla de dos componentes principales, obtenido a partir de cultivos de *Actinoplanes auranticolor* ATCC 31011

prazarelixum

prazarelix — *N*-acetyl-3-(2-naphthyl)-D-alanyl-*p*-chloro-D-phenylalanyl-3-(3-pyridyl)-D-alanyl-L-seryl-*p*-[(5-amino-*s*-triazol-3-yl)amino]-L-phenylalanyl-*p*-[(5-amino-*s*-triazol-3-yl)amino]-D-phenylalanyl-L-leucyl-N^6-isopropyl-L-lysyl-L-prolyl-D-alaninamide

prazarélix — [*N*-acétyl-3-(naphtalén-2-yl)-D-alanyl]-(4-chloro-D-phénylalanyl)-[3-(pyridin-3-yl)-D-alanyl]-L-séryl-[4-[(5-amino-1*H*-1,2,4-triazol-3-yl)amino]-L-phénylalanyl]-[4-[(5-amino-1*H*-1,2,4-triazol-3-yl)amino]-D-phénylalanyl]-L-leucyl-[N^6-(1-méthyléthyl)-L-lysyl]-L-prolyl-D-alaninamide

prazarelix — *N*-acetil-3-(2-naftil)-D-alanil-*p*-cloro-D-fenilalanil-3-(3-piridil)-D-alanil-L-seril-*p*-[(5-amino-*s*-triazol-3-il)amino]-L-fenilalanil-*p*-[(5-amino-*s*-triazol-3-il)amino]-D-fenilalanil-L-leucil-N^6-isopropil-L-lisil-L-prolil-D-alaninamida

$C_{80}H_{102}ClN_{23}O_{12}$



ranpirnasum

ranpirnase — ribonuclease (*Rana pipiens*)

ranpirnase — ribonucléase (*Rana pipiens*)

ranpirnasa — ribonucleasa (*Rana pipiens*)

$C_{520}H_{812}N_{142}O_{156}S_9$



rasburicasum

rasburicase — urate oxydase (tetramer of the *N*-acetylpolypeptide of 301 amino acids)

rasburicase — urate oxydase (tétramère du *N*-acétylpolypeptide de 301 amino-acides)

rasburicasa — urato oxidasa (tétramero del *N*-acetilpolipeptido de 301 amino-ácidos)

$C_{1523}H_{2383}N_{417}O_{462}S_7$ (monomer)

Ac

SAVKAARYGK DNVRVYKVHK DEKTGVQTVY EMTVCVLLEG
EIETSYTKAD NSVIVATDSI KNTIYITAKQ NPVTPPELFG
SILGTHFIEK YNHIHAAHVN IVCHRWTRMD IDGKPHPHSF
IRDSEEKRNV QVDVVEGKGI DIKSSLSGLT VLKSTNSQFW
GFLRDEYTTL KETWDRILST DVDATWQWKN FSGLQEVRSH
VPKFDATWAT AREVTLKTFA EDNSASVQAT MYKMAEQILA
RQQLIETVEY SLPNKHYFEI DLSWHKGLQN TGKNAEVFAP
QSDPNGLIKC TVGRSSLKSK L

rovelizumabum

rovelizumab — immunoglobulin G4, anti-(human CD11 (antigen)/integrin β_2) (human-mouse monoclonal Hu23F2G γ4-chain), disulfide with human-mouse monoclonal Hu23F2G κ-chain, dimer

rovélizumab — immunoglobuline G4, anti-(antigène CD11 humain ou intégrine β_2) (chaîne γ4 de l'anticorps monoclonal de souris Hu23F2G, humanisé), dimère du disulfure avec la chaîne κ de l'anticorps monoclonal de souris Hu23F2G, humanisé

rovelizumab — inmunoglobulina G4, anti-(antígeno CD11 humano o integrina β_2) (cadena γ4 del anticuerpo monoclonal de ratón Hu23F2G, humanizado), dímero del disulfuro con la cadena κ del anticuerpo monoclonal de ratón Hu23F2G, humanizado

sarakalimum

sarakalim — *N*-[[2,2-dimethyl-4-(2-oxo-1(2*H*)-pyridyl)-6-(trifluoromethyl)-2*H*-1-benzopyran-3-yl]methyl]acetohydroxamic acid

sarakalim — *N*-[[2,2-diméthyl-4-(2-oxopyridin-1(2*H*)-yl)-6-(trifluorométhyl)-2*H*-chromén-3-yl]méthyl]-*N*-hydroxyacétamide

sarakalim — ácido *N*-[[2,2-dimetil-4-(2-oxo-1(2*H*)-piridil)-6-(trifluorometil)-2*H*-1-benzopiran-3-il]metil]acetohidroxámico

$C_{20}H_{19}F_3N_2O_4$



selamectinum

selamectin

(2a*E*,4*E*,5'*S*,6*S*,6'*S*,7*S*,8*E*,11*R*,13*R*,15*S*,17a*R*,20a*R*,20b*S*)-6'-cyclohexyl-7-[(2,6-dideoxy-3-*O*-methyl-α-L-*arabino*-hexopyranosyl)oxy]-3',4',5',6,6',7,10,11,14,15,20a,20b-dodecahydro-20b-hydroxy-5',6,8,19-tetramethylspiro[11,15-methano-2*H*,13*H*,17*H*-furo[4,3,2-*pq*][2,6]= benzodioxacyclooctadecin-13,2'-[2*H*]pyran]-17,20(17a*H*)-dione 20-oxime

sélamectine

(2a*E*,4*E*,5'*S*,6*S*,6'*S*,7*S*,8*E*,11*R*,13*R*,15*S*,17a*R*,20a*R*,20b*S*)-6'-cyclohexyl-20b-hydroxy-5',6,8,19-tétraméthyl-7-[(3-*O*-méthyl-2,6-didésoxy-α-L-*arabino*-hexopyranosyl)oxy]-3',4',5',6,6',7,10,11,14,15,20a,20b-dodécahydro= spiro[11,15-méthano-2*H*,13*H*,17*H*-furo[4,3,2-*pq*][2,6]benzodioxa= cyclooctadécène-13,2'-[2*H*]pyrane]-17,20(17a*H*)-dione (*Z*)-20-oxime

selamectina

20-oxima de (2a*E*,4*E*,5'*S*,6*S*,6'*S*,7*S*,8*E*,11*R*,13*R*,15*S*,17a*R*,20a*R*,20b*S*)-6'-ciclohexil-7-[(2,6-didesoxi-3-*O*-metil-α-L-*arabino*-hexopiranosil)oxi]-3',4',5',6,6',7,10,11,14,15,20a,20b-dodecahidro-20b-hidroxi-5',6,8,19-tetrametilespiro[11,15-metano-2*H*,13*H*,17*H*-furo[4,3,2-*pq*][2,6]= benzodioxaciclooctadecin-13,2'-[2*H*]piran]-17,20(17a*H*)-diona

$C_{43}H_{63}NO_{11}$



sibrotuzumabum

sibrotuzumab

immunoglobulin G1, anti-(human FAP (fibroblast activation protein)) (human-mouse monoclonal BIBH1 γ1-chain), disulfide with human-mouse monoclonal BIBH1 κ-chain, dimer

sibrotuzumab

immunoglobuline G1, anti-(FAP (protéine activant le fibroblaste) humaine) (chaîne γ1 de l'anticorps monoclonal de souris BIBH1, humanisé), dimère du disulfure avec la chaîne κ de l'anticorps monoclonal de souris BIBH1, humanisé

sibrotuzumab

inmunoglobulina G1, anti-(FAP humano (proteína de activación de los fibroblastos)) (cadena γ1 del anticuerpo monoclonal de ratón BIBH1), dímero del disulfuro con la cadena κ del anticuerpo monoclonal de ratón BIBH1

siramesinum

siramesine

1'-[4-[1-(*p*-fluorophenyl)indol-3-yl]butyl]spiro[phthalan-1,4'-piperidine]

siramésine

1'-[4-[1-(4-fluorophényl)-1*H*-indol-3-yl]butyl]spiro[isobenzofurane-1(3*H*),4'-pipéridine]

siramesina

1'-[4-[1-(*p*-fluorofenil)indol-3-il]butil]espiro[ftalan-1,4'-piperidina]

$C_{30}H_{31}FN_2O$



sulisatinum

sulisatin

3,3-bis(*p*-hydroxyphenyl)-7-methyl-2-indolinone bis(hydrogen sulfate) (ester)

sulisatine

bis(hydrogénosulfate) de 4,4'-(7-méthyl-2-oxo-1,2-dihydro-3*H*-indol-3-ylidène)diphényle

sulisatina

bis(hidrogenosulfato) éster de 3,3-bis(*p*-hidroxifenil)-7-metil-2-indolinona

$C_{21}H_{17}NO_9S_2$



talnetantum

talnetant

N-[(*S*)-α-ethylbenzyl]-3-hydroxy-2-phenylcinchoninamide

talnétant

3-hydroxy-2-phényl-*N*-[(1*S*)-1-phénylpropyl]quinoléine-4-carboxamide

talnetant

N-[(*S*)-α-etilbencil]-3-hidroxi-2-fenilcinconinamida

$C_{25}H_{22}N_2O_2$



tandaminum

tandamine — 1-[2-(dimethylamino)ethyl]-9-ethyl-1,3,4,9-tetrahydro-1-methylthiopyrano[3,4-*b*]indole

tandamine — 2-[(1*RS*)-9-éthyl-1-méthyl-1,3,4,9-tétrahydrothiopyrano[3,4-*b*]indol-1-yl]-*N*,*N*-diméthyléthanamine

tandamina — 1-[2-(dimetilamino)etil]-9-etil-1,3,4,9-tetrahidro-1-metiltiopirano[3,4-*b*]indol

$C_{18}H_{26}N_2S$



and enantiomer
et énantiomère
y enantiómero

teopranitolum

teopranitol — 1,4:3,6-dianhydro-2-deoxy-2-[[3-(1,2,3,6-tetrahydro-1,3-dimethyl-2,6-dioxopurin-7-yl)propyl]amino]-L-iditol 5-nitrate

téopranitol — nitrate de (3*S*,3a*S*,6*S*,6a*R*)-6-[[3-(1,3-diméthyl-2,6-dioxo-1,2,3,6-tétrahydro-7*H*-purin-7-yl)propyl]amino]hexahydrofuro[3,2-*b*]furan-3-yle

teopranitol — 5-nitrato de 1,4:3,6-dianhidro-2-desoxi-2-[[3-(1,2,3,6-tetrahidro- 1,3-dimetil-2,6-dioxopurin-7-il)propil]amino]-L-iditol

$C_{16}H_{22}N_6O_7$



tesmilifenum

tesmilifene — 2-[(α-phenyl-*p*-tolyl)oxy]triethylamine

tesmilifène — 2-(4-benzylphénoxy)-*N*,*N*-diéthyléthanamine

tesmilifeno — 2-[(α-fenil-*p*-tolil)oxi]trietilamina

$C_{19}H_{25}NO$



tezosentanum

tezosentan

N-[6-(2-hydroxyethoxy)-5-(*o*-methoxyphenoxy)-2-[2-(1*H*-tetrazol-5-yl)-4-pyridyl]-4-pyrimidinyl]-5-isopropyl-2-pyridinesulfonamide

tézosentan

N-[6-(2-hydroxyéthoxy)-5-(2-méthoxyphénoxy)-2-[2-(1*H*-tétrazol-5-yl)pyridin-4-yl]pyrimidin-4-yl]-5-(1-méthyléthyl)pyridine-2-sulfonamide

tezosentano

N-[6-(2-hidroxietoxi)-5-(*o*-metoxifenoxi)-2-[2-(1*H*-tetrazol-5-il)-4-piridil]-4-pirimidinil]-5-isopropil-2-piridinasulfonamida

$C_{27}H_{27}N_9O_6S$



ticarcillinum

ticarcillin

N-(2-carboxy-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-6-yl)-3-thiophenemalonamic acid

ticarcilline

acide (2*S*,5*R*,6*R*)-6-[[(2*R*)-carboxy(thiophén-3-yl)acétyl]amino]-3,3-diméthyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylique

ticarcilina

ácido *N*-(2-carboxi-3,3-dimetil-7-oxo-4-tia-1-azabiciclo[3.2.0]hept-6-il)-3-tiofenomalonámico

$C_{15}H_{16}N_2O_6S_2$



tienocarbinum

tienocarbine — 7,8,9,10-tetrahydro-1,9-dimethyl-6*H*-pyrido[4,3-*b*]thieno[3,2-*e*]indole

tiénocarbine — 1,9-diméthyl-7,8,9,10-tétrahydro-6*H*-pyrido[4,3-*b*]thiéno[3,2-*e*]indole

tienocarbina — 7,8,9,10-tetrahidro-1,9-dimetil-6*H*-pirido[4,3-*b*]tieno[3,2-*e*]indol

$C_{15}H_{16}N_2S$



tocladesinum

tocladesine — 8-chloroadenosine 3',5'-cyclic phosphate

tocladésine — 3',5'-hydrogénophosphate cyclique de 8-chloroadénosine

tocladesina — 3',5'- hidrógenofosfato cíclico de 8-cloroadenosina

$C_{10}H_{11}ClN_5O_6P$



triclofosum

triclofos — 2,2,2-trichloroethyl dihydrogen phosphate

triclofos — dihydrogénophosphate de 2,2,2-trichloroéthyle

triclofós — dihidrógenofosfato de 2,2,2-tricloroetilo

$C_2H_4Cl_3O_4P$



triflocinum

triflocin — 4-(α,α,α-trifluoro-*m*-toluidino)nicotinic acid

triflocine — acide 4-[[3-(trifluorométhyl)phényl]amino]pyridine-3-carboxylique

triflocina — ácido 4-(α,α,α-trifluoro-*m*-toluidino)nicotínico

$C_{13}H_9F_3N_2O_2$



trimecainum

trimecaine — *N*-(α-diethylaminoacetyl)-2,4,6-trimethylaniline

trimécaïne — 2-(diéthylamino)-*N*-(2,4,6-triméthylphényl)acétamide

trimecaína — *N*-(α-diétilaminoacetil)-2,4,6-trimetilanilina

$C_{15}H_{24}N_2O$



troxacitabinum

troxacitabine — (-)-1-[(2*S*,4*S*)-2-(hydroxymethyl)-1,3-dioxolan-4-yl]cytosine

troxacitabine — (-)-4-amino-1-[(2*S*,4*S*)-2-(hydroxyméthyl)-1,3-dioxolan-4-yl]pyrimidin-2(1*H*)-one

troxacitabina — (-)-1-[(2*S*,4*S*)-2-(hidroximetil)-1,3-dioxolan-4-il]citosina

$C_8H_{11}N_3O_4$



zolazepamum

zolazepam	4-(*o*-fluorophenyl)-6,8-dihydro-1,3,8-trimethylpirazole[3,4-*e*][1,4]diazepin-7(1*H*)-one
zolazépam	4-(2-fluorophényl)-1,3,8-triméthyl-6,8-dihydropyrazolo[3,4-*e*][1,4]diazépin-7(1*H*)-one
zolazepam	4-(*o*-fluorofenil)-6,8-dihidro-1,3,8-trimetilpirazolo[3,4-*e*][1,4]diazepin-7(1*H*)-ona

$C_{15}H_{15}FN_4O$



AMENDMENTS TO PREVIOUS LISTS
MODIFICATIONS APPORTÉES AUX LISTES ANTÉRIEURES
MODIFICACIONES A LAS LISTAS ANTERIORES

Recommended International Nonproprietary Names (Rec. INN): List 38
Dénominations communes internationales recommandées (DCI Rec.): Liste 38
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 38
(WHO Drug Information, Vol. 11, No. 3, 1997)

p. 166 **faralimomabum**

faralimomab	*replace the description by the following:* immunoglobulin G1, anti-(human interferon type I receptor) (mouse monoclaonal 64G12 γ1-chain), disulfide with mouse monoclonal 64G12 light chain, dimer
faralimomab	*remplacer la description par la suivante:* immunoglobuline G1, anti-(récepteur humain des interférons de type I) (chaîne γ1 de l'anticorps monoclonal de souris 64G12), dimère du disulfure avec la chaîne légère de l'anticorps monoclonal de souris 64G12
faralimomab	*sustitúyase la descripción por la siguiente:* inmunoglobulina G1, anti-(receptor humano de los interferones del tipo I) (cadena γ1 del anticuerpo monoclonal de ratón 64G12), dímero del disulfuro con la cadena ligera del anticuerpo monoclonal de ratón 64G12

p. 169 **keliximab**

keliximab	*replace the description by the following:* immunoglobulin G1, anti-(human CD4 (antigen)) (human-macaca monoclonal CE9.1 γ1-chain), disulfide with human-macaca monoclonal CE9.1 λ-chain, dimer
kéliximab	*remplacer la description par la suivante:* immunoglobuline G1, anti-(antigène CD4 humain) (chaîne γ1 de l'anticorps monoclonal chimérique homme-macaque CE9.1), dimère du disulfure avec la chaîne λ de l'anticorps monoclonal chimérique homme-macaque CE9.1
keliximab	*sustituyase la descripción por la siguiente:* inmunoglobulina G1, anti-(antigeno CD4 humano) (cadena γ1 del anticuerpo monoclonal hombre-macaco CE9.1), dímero del disulfuro con la cadena λ del anticuerpo monoclonal quimérico hombre-macaco CE9.1

p. 172 **lintuzumabum**

lintuzumab	*replace the description by the following:* immunoglobulin G1, anti-(human CD33 (antigen)) (human-mouse monoclonal HuM195 γ1-chain), disulfide with human-mouse monoclonal HuM195 κ-chain, dimer
lintuzumab	*remplacer la description par la suivante:* immunoglobuline G1, anti-(antigène CD33 humain) (chaîne γ1 de l'anticorps monoclonal de souris HuM195, humanisé), dimère du disulfure avec la chaîne κ de l'anticorps monoclonal de souris HuM195, humanisé
lintuzumab	*sustituyase la descripción por la siguiente:* inmunoglobulina G1, anti-(antigeno CD33 humano) (cadena γ1 del anticuerpo monoclonal hombre-ratón HuM195), dímero del disulfuro con la cadena κ del anticuerpo monoclonal hombre-ratón HuM195

Recommended International Nonproprietary Names (Rec. INN): List 41
Dénominations communes internationales recommandées (DCI Rec.): Liste 41
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 41
(WHO Drug Information, Vol. 13, No. 1, 1999)

p. 53 **satumomabum**

satumomab	*replace the description by the following:* immunoglobulin G1, anti-(human tumor-associated glycoprotein 72) (mouse monoclonal B72.3 γ1- chain), disulfide with mouse monoclonal B72.3 light chain, dimer
satumomab	*remplacer la description par la suivante:* immunoglobuline G1, anti-(glycoprotéine 72 humaine associée aux tumeurs) (chaîne γ1 de l'anticorps monoclonal de souris B72.3), dimère du disulfure avec la chaîne légère de l'anticorps monoclonal de souris B72.3
satumomab	*sustitúyase la descripción por la siguiente:* inmunoglobulina G1, anti-(glicoproteína 72 humana asociada a los tumores) (cadena γ1 del anticuerpo monoclonal de ratón B72.3), dímero del disulfuro con la cadena ligera del anticuerpo monoclonal de ratón B72.3

Procedure and Guiding Principles / Procédure et Directives / Procedimientos y principios generales

The text of the *Procedures for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances* and *General Principles for Guidance in Devising International Nonproprietary Names for Pharmaceutical Substances* will be reproduced in uneven numbers of proposed INN lists only.

Les textes de la *Procédure à suivre en vue de choix de dénominations communes internationales recommandées pour les substances pharmaceutiques* et des *Directives générales pour la formation de dénominations communes internationales applicables aux substances pharmaceutiques* ont été publiés avec la liste 81 des DCI proposées et seront, à nouveau, publiés avec la prochaine liste des DCI proposées.

El texto de los *Procedimientos de selección de denominaciones comunes internacionales recomendadas para las sustancias farmacéuticas* y de los *Principios generales de orientación para formar denominaciones comunes internacionales para sustancias farmacéuticas* aparece solamente en los números impares de las listas de DCI propuestas.